Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease

BACKGROUND/AIMS: The current treatment for anemia associated with chronic kidney disease (CKD) includes the administration of erythropoiesis stimulating agents (ESAs) combined with iron supplementation. Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has potential to treat anemi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Nephron Clin Pract
Asıl Yazarlar: Akizawa, Tadao, Macdougall, Iain C., Berns, Jeffrey S., Yamamoto, Hiroyasu, Taguchi, Megumi, Iekushi, Kazuma, Bernhardt, Thomas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: S. Karger AG 2019
Konular:
Clinical Practice: Original Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6979436/
https://ncbi.nlm.nih.gov/pubmed/31387097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000502012
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller